Research at the Interface

In this project, we will be developing the first PROTAC Chimera for use against novel bacterial hosts, specifically Mycobacterium tuberculosis.

In this project, we are undertaking high throughput screening to find novel architectures for development as novel antibacterials. Once identified we undertake the necessary molecular biology to identify the biological target and its role. Notwithstanding this, we also develop novel small molecule inhibitors of enzymes identified as potentially druggable targets in these bacteria.

We have a number of projects looking at generating diagnostics ([18F] PET tracers, fluorogenic compounds) to study neurodegenerative diseases, such as Alzheimers and Parkinsons.

In this project we are building on our earlier work developing small molecules capable of protecting cells, specifically the mitochondria, from reactive oxygen species. This project will involve the synthesis and screening of molecule analogues and subsequent pharmacokinetic studies for their utility as commercial additives